Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EVX4 | ISIN: US6409791000 | Ticker-Symbol:
NASDAQ
20.05.24
21:59 Uhr
9,690 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEUMORA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NEUMORA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NEUMORA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression52Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant...
► Artikel lesen
07.05.Neumora Therapeutics, Inc. - 10-Q, Quarterly Report1
07.05.Neumora Therapeutics GAAP EPS of -$0.341
07.05.Neumora Therapeutics, Inc. - 8-K, Current Report-
07.05.Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update96On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024...
► Artikel lesen
18.04.Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success3
16.04.Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug1
16.04.FDA halts Neumora's schizophrenia drug trial over convulsions in rabbits2
15.04.Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug3
15.04.Neumora's schizophrenia drug hit with clinical hold2
15.04.Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?1
15.04.Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug1
15.04.Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits1
15.04.Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?1
15.04.Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session4
15.04.Neumora Tumbles as Early-Stage Study Put on Clinical Hold1
15.04.FDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-Market1
15.04.Neumora stock slides as FDA puts Phase 1 schizophrenia study on hold1
15.04.Neumora Therapeutics, Inc. - 8-K, Current Report 1
15.04.Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study86WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical...
► Artikel lesen
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1